NKTX

Companies
NASDAQ
Nkarta Inc.
Health Care
Price Chart
Overview

About NKTX

Nkarta Inc is a biopharmaceutical company engaged in developing engineered natural killer (NK) cells to treat cancer and autoimmune diseases. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer. The Company's operations are based in South San Francisco, California.

Market Cap
$465.1M
Volume
864.9K
Avg. Volume
1.2M
P/E Ratio
-1.0227273
Dividend Yield
0.00%
Employees
149.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
1.22
Moderate Correlation
Volatility
High (0.96)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Medium Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for NKTX.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, NKTX shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$465.1M
Volume864.9K
P/E Ratio-1.02
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 15, 2025

PortfolioPilot Analysis

Get AI-powered insights on how NKTX fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025